Name of study:
Purpose of study:
To compare the efficacy of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Is this a pre- or post- market study?:
Is the study of a controlled or observational design?
What is the funding source?:
Where is the study being conducted?
There is no lead institution.
City and State:
When the study is being conducted:
Start Date: 1/2021
End date: 6/2022
What website should a person use to register for the study?
Who should a person contact to register for the study?
Who is sponsoring this study?
What is the identifier for this study on ClinicalTrials.gov?
Page last updated: November 9, 2020